Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy

Liver International

Volumn 24, Issue 1, 2004, Pages 9-15

  Lin, Chih Lin ^a   Liao, Li Ying ^a   Wang, Chaur Shine ^a   Chen, Pei Jer ^b   Lai, Ming Yang ^b   Chen, Ding Shinn ^b   Kao, Jia Horng ^b  

^a JEN AI HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

HBeAg seroconversion; HBV DNA; Hepatitis Bmivudine; Mutant

Indexed keywords

DNA POLYMERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HUMAN; MALE; MOLECULAR EVOLUTION; NONHUMAN; PROMOTER REGION; RECURRENCE RISK; REVERSAL REACTION; SEROCONVERSION; SHORT COURSE THERAPY; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

EID: 84984539156     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.00893.x     Document Type: Article

References (24)

1. Kao J H, Chen D S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
2. Chen D S. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-70.
3. Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, Ng K Y, Wu P C, Dent J C, Barber J, Stephenson S L, Gray D F. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
4. Liaw Y F, Leung N W, Chang T T, Guan R, Tai D I, Ng K Y, Chien R N, Dent J, Roman L, Edmunson S, Lai C L. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
5. Hadziyannis J, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
6. Carman W F, Jacyna M R, Hadziyannis S, Karayiannis P, McGarvey M J, Makris A, Thomas H C. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
7. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with sero-conversion to the antibody against e antigen. J Virol 1990; 64: 1298-303.
8. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102-10.
9. Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-34.
10. Liaw Y F. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12: 67-71.
11. Farrell G LY, McCaughan G. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific consensus on hepatitis B and C. J Gastroenterol Hepatol 2000; 15: 825-41.
12. Kao J H, Chen PJ, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
13. Chen R W, Piiparinen H, Seppanen M, Koskela P, Sarna S, Lappalainen M. Real-time PCR for detection and quantitation of hepatitis B virus DNA. J Med Virol 2001; 65: 250-6.
14. Lok A S, McMahon B J. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
15. Wong D K, Cheung A M, O'Rourke K, Naylor C D, Detsky A S, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e. Ann Intern Med 1993; 119: 312-23.
16. Chien R N, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-4.
17. Leung N W, Lai C L, Chang T T, Guan R, Lee C M, Ng K Y, Lim S G, Wu P C, Dent J, Edmundson S, Condreay L D, Chien R N. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001; 33: 1527-32.
18. Song B C, Suh D J, Lee H C, Chung Y H, Lee Y S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
19. Pichoud C, Berby F, Stuyver L, Petit M A, Trepo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000; 32: 307-16.
20. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987; 57: 231-6.
21. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002; 37: 355.
22. Yamaura T, Tanaka E, Matsumoto A, Rokuhara A, Oraii K, Yoshizawa K, Miyakawa Y, Kiyosawa K. A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter. J Med Virol 2003; 70: 545-52.
23. Chen R Y, Edwards R, Shaw T, Colledge D, Delaney W E T, Isom H, Bowden S. Desmond P, Locarnini S A. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 27-35.
24. Lok A S-F, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi G L, Jovine E, Benardi M, Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.